Johnson & Johnson will “proactively delay the rollout of our vaccine in Europe”, the pharmaceutical company revealed on Tuesday. It follows a handful of reports that link the vaccine to dangerous blood clots. The Centres for Disease Control and Prevention (CDC) has recommended the rollout of the vaccine be freezes in the US while investigations are underway.
The FDA tweeted that it and the Centers for Disease Control and Prevention (CDC) were reviewing “six reported US cases of a rare & severe type of blood clot in individuals after receiving the vaccine. Right now, these adverse events appear to be extremely rare”.
The health body added: “We are recommending a pause in the use of this vaccine out of an abundance of caution.”
The principal aim being to “ensure that the health care provider community is aware of the potential for these adverse events”.
The FDA and CDC also issued a joint statement on Tuesday advising people on the signs of blood clotting look out for.